Skip to content
2000
Volume 15, Issue 2
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Testicular germ cell tumors (TGCTs) are unique to that of most other solid tumors because they are highly curable in the metastatic setting. While the use of cisplatin-based chemotherapy continues to drive cure in this patient population, important improvements in the delivery of therapy, creation of risk-adjusted treatment paradigms, and salvage-therapy options have further enhanced survival as well. The future holds promise for a more multidisciplinary approach to care, through advancements in biochemical markers and a better understanding of how surgical and radiotherapy approaches can integrate into our existing management strategies.

Loading

Article metrics loading...

/content/journals/cctr/10.2174/1573394714666180706150427
2019-08-01
2025-06-19
Loading full text...

Full text loading...

/content/journals/cctr/10.2174/1573394714666180706150427
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test